Search

Your search keyword '"Anfinan, Nisreen M."' showing total 10 results
Start Over Author "Anfinan, Nisreen M."
10 results on '"Anfinan, Nisreen M."'

6. Growing teratoma syndrome with porta hepatis involvement – a case report

Author

Abdulraheem, Ekhlas Ahmed, Sait, Maram K, Sait, Khalid H, Anfinan, Nisreen M, and Elkadi, Osama R

Subjects
endocrine system, endocrine system diseases, malignant germ cell tumor, porta hepatis, growing teratoma syndrome, Case Report, female genital diseases and pregnancy complications
Abstract

Growing teratoma syndrome is a rare entity of tumors, it arises seldomly from ovarian and testicular carcinoma. It presents with disseminating masses of mature teratoma during or following chemotherapy of malignant germ cell tumors. We are reporting a 19-year old presented with recurrent left ovarian mass and supra renal large mass close to the porta hepatis was seen on magnetic resonance imaging. This patient was treated 3 years ago for stage I immature teratoma with left ovarian cystectomy and chemotherapy. Surgical excision of the left ovary and the abdominal mass required meticulous dissection, and the mass was shaved off the porta hepatis with no intraoperative or postoperative complications. Pathology showed mature teratoma. She has no recurrent 5 years after treatment. To the best of our knowledge, this is the first case report describing close relation of growing teratoma syndrome to the porta hepatis, no such case report like this has been reported in our region.

Published
2019

7. Growing teratoma syndrome with porta hepatis involvement – a case report

Author

Abdulraheem,Ekhlas Ahmed, Sait,Maram K, Sait,Khalid H, Anfinan,Nisreen M, Elkadi,Osama R, Abdulraheem,Ekhlas Ahmed, Sait,Maram K, Sait,Khalid H, Anfinan,Nisreen M, and Elkadi,Osama R

Abstract

Ekhlas Ahmed Abdulraheem,1 Maram K Sait,2 Khalid H Sait,2 Nisreen M Anfinan,1 Osama R Elkadi3 1Department of Obstetrics and Gynecology, Gynecology Oncology Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 2Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 3Department of Pathology, Drexel University College of Medicine, PA, USA Abstract: Growing teratoma syndrome is a rare entity of tumors, it arises seldomly from ovarian and testicular carcinoma. It presents with disseminating masses of mature teratoma during or following chemotherapy of malignant germ cell tumors. We are reporting a 19-year old presented with recurrent left ovarian mass and supra renal large mass close to the porta hepatis was seen on magnetic resonance imaging. This patient was treated 3 years ago for stage I immature teratoma with left ovarian cystectomy and chemotherapy. Surgical excision of the left ovary and the abdominal mass required meticulous dissection, and the mass was shaved off the porta hepatis with no intraoperative or postoperative complications. Pathology showed mature teratoma. She has no recurrent 5 years after treatment. To the best of our knowledge, this is the first case report describing close relation of growing teratoma syndrome to the porta hepatis, no such case report like this has been reported in our region. Keywords: malignant germ cell tumor, porta hepatis, growing teratoma syndrome

Published
2019

9. Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agents.

Author

Sait KHW, Mashraqi M, Khogeer AA, Alzahrani O, Anfinan NM, Sait HK, Almutairi A, and Alam Q

Abstract

The human epidermal growth factor (HER2) is a transmembrane receptor that is highly expressed in breast cancer and in different other cancers. Therefore, it is of interest to identify the new HER2 inhibitors from a selected 300 compounds in the ZINC database. The top two hit compounds (ZINC000014780728 (-11.0 kcal/mol) and ZINC000014762512 (-10.8 kcal/mol)) showed a high affinity with HER2 relative to the reference compound (lapatinib (-10.2 kcal/mol)) for further consideration., Competing Interests: None, (© 2020 Biomedical Informatics.)

Published
2020
Full Text
View/download PDF

10. Uterine sarcoma. Clinico-pathological characteristics and outcome.

Author

Sait HK, Anfinan NM, El Sayed ME, Alkhayyat SS, Ghanem AT, Abayazid RM, and Sait KH

Subjects
Adult, Aged, Carcinosarcoma pathology, Carcinosarcoma therapy, Chemotherapy, Adjuvant, Cohort Studies, Disease-Free Survival, Female, Humans, Leiomyosarcoma pathology, Leiomyosarcoma therapy, Middle Aged, Neoplasm Grading, Neoplasm Staging, Ovariectomy, Radiotherapy, Adjuvant, Retrospective Studies, Rhabdomyosarcoma pathology, Rhabdomyosarcoma therapy, Salpingectomy, Sarcoma pathology, Sarcoma, Endometrial Stromal pathology, Sarcoma, Endometrial Stromal therapy, Treatment Outcome, Uterine Neoplasms pathology, Hysterectomy, Sarcoma therapy, Uterine Neoplasms therapy
Abstract

Objectives: To investigate the clinical and histopathological characteristics, with the prognostic factors, treatment outcome, pattern of relapse, and survival analysis of uterine sarcoma patients., Methods: All patients with histologically proven uterine sarcoma were identified using the database at King Abdulaziz University Hospital, Jeddah, Saudi Arabia between January 2000 and December 2012., Results: A total of 36 patients with uterine sarcoma were reviewed. The median age of all patients was 57 years, and the mean age was 57.72+/-13.17 years. Carcinosarcoma was reported in 21 patients (58%), leiomyosarcoma in 7 (19%), undifferentiated endometrial sarcoma in 6 (17%), and rhabdomyosarcoma in 2 (6%). Approximately half of the patients were stages III and IV (28% and 25%), while 15 patients (41%) were stage I; only 2 patients (6%) were stage II. The surgical treatment was hysterectomy and bilateral salpingoophorectomy (H+BSO) plus staging in 18 patients (50%), while in 4 patients (19%), H+BSO plus debulking was performed. Adjuvant chemotherapy was given in 24 (69%) and adjuvant radiotherapy in 5 (14%) cases, At a median follow-up period of 13.5 months, 8 patients (22%) relapsed. The 2-year disease-free survival (DFS) rate was 22% and the 5-year was 14%. In the multivariate analysis, the advanced stages  (p=0.015) and lymph vascular invasion (p=0.0001) were associated with poor DFS, while the use of chemotherapy significantly improved the DFS (p=0.027)., Conclusions: The poor outcome of high-grade uterine sarcoma patients was identified, and only one third of patients (30%) survived for 2 years. This finding necessitates the need for more aggressive tools to fight this disease.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results